spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Gyros Protein Technologies Appoints Frank Witney as Chairman

Gyros Protein Technologies

Appointment supports the goals of organic growth and expansion through acquisitions

Uppsala, Sweden, 20 June 2016: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, today announced the appointment of Dr Frank Witney as Chairman of the Board. Dr Witney’s appointment is a key milestone in Gyros Protein Technologies’ strategy to build upon the Company’s strong market position through ongoing development of innovative products, commercial expansion, and growth via acquisition. David Patteson, prior chairman of Protein Technologies, Inc. remains as a Director.

Dr Witney has over 30 years of experience in leadership and innovation in the life science industry. Most recently he was President and CEO of Affymetrix, which was acquired by Thermo Fisher Scientific in March 2016. Prior to this, Dr Witney was President and Chief Executive Officer of Dionex, leading to the company’s successful acquisition by Thermo Fisher Scientific in 2011. Earlier executive roles include President and CEO of Panomics, acquired by Affymetrix, and COO at Packard Biosciences, acquired by PerkinElmer, after which he served as President of their Life Sciences Group. Earlier in his career Dr Witney held a series of positions at Bio-Rad Laboratories, including Group Operations Manager of the Life Science Group, leading efforts to enter rapidly growing markets for proteomic and bioassay technologies.

Dr Witney holds a doctorate in molecular and cell biology from Indiana University, and was a post-doctoral fellow at the National Institutes of Health. He is also a member of the Board of Directors of Cerus Corporation and Exagen Diagnostics, Inc.

Dan Calvo, CEO of Gyros Protein Technologies, commented: “We are delighted that Frank has joined as Chairman. He brings with him a wealth of experience and knowledge in the field, and his guidance will be invaluable as we work to build Gyros Protein Technologies following the merger earlier this year.”

Dr Witney said: “I am very pleased to join Gyros Protein Technologies at this exciting time for the business. The Company has a clear vision, a history of strong and profitable growth, and a robust strategy. I look forward to working with Dan and the Board in their efforts to grow the newly combined platform and enhance shareholder value.”

Established in March 2016 by the merger of Gyros AB and Protein Technologies, Inc., Gyros Protein Technologies combines Gyros’ microfluidics, systems development and immunoassay expertise with Protein Technologies’ deep knowledge in developing and manufacturing instruments for peptide synthesis. The Company provides customers an unrivaled range of peptide synthesis and bioanalytical tools for biotherapeutics discovery, development and bioprocessing

Both Gyros and Protein Technologies introduced new platforms in 2015. Gyros launched Gyrolab xPlore™, an automated, nanoliter-scale, single CD immunoassay system, while Protein Technologies introduced the Prelude® X which incorporates novel, efficient heating and UV monitoring technology for economical, rapid synthesis of even the most difficult peptides.
phone +46 (0)18 56 63 00
email information@gyros.com
web www.gyros.com
email Gyros AB, Uppsala Science Park, SE-751, 83 Uppsala, Sweden
 
Print this page
Send to a friend
   
spacer
News and Press Releases

ChemAxon and AWS simplify getting scientists moving on the cloud

Listen to a talk by Paul Underwood of AWS introducing Biotech Blueprint, a cloud based solution for cheminformatics. The technology for novel compound registration is provided by ChemAxon.
More info >>


White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

Industry Events

Clinical Innovation Partnerships 2018

3-4 July 2018, Radisson Blu Hotel, Zurich Airport

Clinical Innovation Partnerships is the only event for senior clinical operations and procurement professionals driving innovation in their clinical trials. It is where the pharma, CRO and vendor clinical trials ecosystem meet to drive innovation in digitalisation, tech and partnering to improve patient experience and reduce trial cost and time.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement